Before the Food and Drug Administration (FDA) approved the use of intravenous (IV)
recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke in 1996, most of …

Nearly 8 years have passed since the US Food and Drug Administration (FDA) released
recombinant tissue plasminogen activator (rt-PA) for treatment of patients with acute …

Modern day therapy of acute ischemic stroke is based upon intravenous thrombolysis, which
has altered management of this potentially devastating disease. The urgent treatment of …

Life is short, and Art long; the crisis fleeting; experience perilous, and decision difficult. The
physician must not only be prepared to do what is right himself, but also to make the patient …

The National Institute of Neurological Disorders and Stroke (NINDS) trial was
groundbreaking. 1 It demonstrated that stroke patients could be admitted to hospital …

Acta Neurol Taiwan 2009; 18: 1-2 in-hospital delays (door-to-needle time) and increase the
percentage of eligible patients with acute ischemic stroke receiving thrombolytic therapy …

Outcome of intravenous recombinant tissue plasminogen activator (rt-PA) for acute ischemic
stroke in Thailand - Journal of Stroke and Cerebrovascular Diseases Skip to Main Content Skip …

Recombinant tissue plasminogen activator (rt-PA, also known as alteplase; Actilyse®) is the
first and only licensed thrombolytic approved for use in acute ischaemic stroke in the UK …

Thombolytic therapy for acute ischemic stroke is an intuitively attractive idea that has been
under investigation since the 1950s. The advent of computed tomography, which allowed …

The controversial field of interventional stroke neurology has attracted considerable interest
within the stroke community, but no endovascular interventional therapies have proved to be …